PART I . Overview We are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered sa...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001493152-26-010585 | EDGAR | 84K words |
| 2025-03-13 | 2024-12-31 | 0001493152-25-010136 | EDGAR | — |
| 2024-03-13 | 2023-12-31 | 0001493152-24-009769 | EDGAR | — |
| 2023-03-17 | 2022-12-31 | 0001493152-23-008010 | EDGAR | — |
| 2022-03-21 | 2021-12-31 | 0001493152-22-007319 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001493152-25-021759 | EDGAR | 18K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023333 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001641172-25-010099 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044537 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001493152-24-031158 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001493152-24-018162 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001493152-23-039523 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028059 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001493152-23-016268 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031392 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001493152-22-021562 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001493152-22-012931 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001493152-26-015079 | EDGAR | 1K words |
| 2026-03-24 | 0001493152-26-012372 | EDGAR | — |
| 2026-02-27 | 0001493152-26-008326 | EDGAR | — |
| 2026-02-12 | 0001493152-26-006330 | EDGAR | — |
| 2026-01-20 | 0001493152-26-002850 | EDGAR | — |
| 2026-01-08 | 0001493152-26-001004 | EDGAR | — |
| 2026-01-02 | 0001493152-26-000106 | EDGAR | — |
| 2025-12-23 | 0001493152-25-029107 | EDGAR | — |
| 2025-11-12 | 0001493152-25-021758 | EDGAR | — |
| 2025-09-04 | 0001493152-25-012630 | EDGAR | — |
110 total filings indexed. 83 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001857044 |
| Ticker | INDP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.indaptusrx.com |
| Listed | 2021-08-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report